Monoclonal antibodies against macrophage colony-stimulating factor (M-CSF) diminish the number of circulating intermediate and nonclassical (CD14highCD16mid/CD14midCD16high) monocytes in RA patients [23]. Here, CSF1 is linked to rheumatoid arthritis.